We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CSTI-500
Previous Study | Return to List | Next Study

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05504395
Recruitment Status : Recruiting
First Posted : August 17, 2022
Last Update Posted : December 7, 2022
Sponsor:
Information provided by (Responsible Party):
ConSynance Therapeutics

Brief Summary:
The purpose of this Phase 1 study is to evaluate the pharmacokinetics (PK) and safety of a single dose of CSTI-500 10 mg in subjects with Prader-Willi syndrome (PWS) between 13 and 50 years of age with a genetically confirmed diagnosis of PWS.

Condition or disease Intervention/treatment Phase
Prader-Willi Syndrome Drug: CSTI-500 Phase 1

Detailed Description:
This is an open-label, single center, Phase 1 study to evaluate the PK and safety of a 10 mg single oral dose of CSTI-500, a triple monoamine reuptake inhibitor (TRI), in patients with genetically confirmed PWS. The study will consist of a Screening Period of up to 1-3 days prior to the Baseline Visit (Visit 2). In addition to the Screening Visit (Visit 1), eligible subjects will attend five in-clinic site visits for PK blood draws and safety assessments over a 6-day period. At Visit 2 all subjects will receive one single oral dose of CSTI-500 10 mg. Approximately 14 patients aged 13 to 50 years who meet all eligibility criteria will receive one single dose of CSTI-500.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1, Single Center, Open Label, Single Dose, Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome
Actual Study Start Date : November 14, 2022
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : January 15, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CSTI-500 10mg
All eligible subjects will be administered a single oral dose of CSTI-500 10 mg at Visit 2
Drug: CSTI-500
Single 10 mg capsule
Other Name: AMR-001181




Primary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose ]
    Maximum observed plasma concentration following drug administration determined directly from the concentration-time profile.

  2. AUC0-72 [ Time Frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose ]
    Area under the plasma-drug concentration-time curve from pre-dose (time 0) to 72 hours after drug administration

  3. AUC0-inf [ Time Frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose ]
    Area under the plasma-drug concentration-time curve from pre-dose (time 0) extrapolated to infinite time

  4. CSTI-500 plasma concentration [ Time Frame: 1 hour post-dose ]
  5. CSTI-500 plasma concentration [ Time Frame: 2 hour post-dose ]
  6. CSTI-500 plasma concentration [ Time Frame: 4 hour post-dose ]
  7. CSTI-500 plasma concentration [ Time Frame: 8 hour post-dose ]
  8. CSTI-500 plasma concentration [ Time Frame: 12 hour post-dose ]
  9. CSTI-500 plasma concentration [ Time Frame: 24 hour post-dose ]
  10. CSTI-500 plasma concentration [ Time Frame: 48 hour post-dose ]
  11. CSTI-500 plasma concentration [ Time Frame: 72 hour post-dose ]
  12. CSTI-500 plasma concentration [ Time Frame: 144 hour post-dose ]

Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: From pre-dose to 15 days post-dose ]
    Number of participants with TEAEs, defined as an adverse event (AE) that is new or worsened in severity after the dose of study drug. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized by system organ class, preferred term, and treatment.

  2. Incidence of clinically significant findings in physical examinations [ Time Frame: Screening to 12, 24, 48, 72, and 144 hours post-dose ]
  3. Incidence of clinically significant findings in vital signs [ Time Frame: Screening and pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose ]
    Participants will be assessed for any clinically significant changes in vital parameters (blood pressure, heart rate in supine and standing position, respiratory rate, and body temperature). This also includes evaluation of postural orthostatic tachycardic syndrome.

  4. Incidence of clinically significant findings in laboratory values [ Time Frame: Screening to 24, 48, 72, and 144 hours post-dose ]
    Laboratory evaluations include hematology, thyroid function, and chemistry blood and urine laboratory tests.

  5. Incidence of clinically significant findings in 12-lead electrocardiograms (ECGs) [ Time Frame: Screening and pre-dose to 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose ]
  6. Comparison of CSTI-500 Cmax values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects [ Time Frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose ]
  7. Comparison of CSTI-500 AUC0-72 values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects [ Time Frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose ]
  8. Comparison of CSTI-500 AUC0-inf values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects [ Time Frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects (13-50 years of age at screening) with a documented medical record history of PWS confirmed by genetic testing.
  • Subject must have a reliable caregiver/parent to bring the subject to the site for the visits, remain with the subject during visit times when allowed to be with the subject and respond to any questions during the visits.
  • Female subjects must not be pregnant or lactating and be willing to use double barrier birth control method throughout the study.
  • A normal supine systolic blood pressure must be ≤140 mmHg and ≥100 mmHg; diastolic blood pressure must be ≤80 mmHg and ≥60 mmHg at Screening. Pulse rate must be ≥50 bpm and ≤100 bpm and pulse rate increase on standing must be within acceptable range.
  • All concomitant medications including blood pressure medications and type 2 diabetic medications must be stable for ≥3 months prior to screening (≤10% change). Supplements and vitamins are not considered concomitant medications for eligibility purposes.

Exclusion Criteria:

  • Participation in any clinical study with an investigational drug/device within 3 months prior to screening or during the study.
  • Recent use (within 3 months) of weight loss agents including prescription, herbal medications, and weight loss supplements.
  • Major surgery within 6 months of screening or planned during the study or history of bariatric surgery.
  • Any malignancy in the 2 years prior to screening (excluding basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
  • Current liver, pulmonary, cardiac, or GI disease that would be expected to adversely affect study participation. Stable disease, e.g., asthma or controlled hypertension is not excluded. Liver disease or liver injury as indicated by abnormal liver function tests, ALT, AST, alkaline phosphatase, or serum bilirubin (≥3X ULN for any of these tests).
  • Unexplained history or presence of combination of unexplained symptoms e.g., dizziness, syncope, fatigue, palpitations/tachycardia, headaches, or exercise intolerance.
  • Heart failure classified per the New York Heart Association (NYHA) level II or greater.
  • Myocardial infarction, stroke, or confirmed TIA within the last 5 years.
  • Uncontrolled Type 2 diabetes as defined by HbA1c ≥ 9% at Screening.
  • Insulin-dependent Type 1 diabetes.
  • Subjects with a history of any suicidal behavior.
  • Inability to swallow the oral capsule whole with water.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05504395


Contacts
Layout table for location contacts
Contact: Lois B Rosenberger, PhD 859 426 5035 lrosenberger@lbr-regulatory.com

Locations
Layout table for location information
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Elizabeth Roof         
Sponsors and Collaborators
ConSynance Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Italo Biaggioni, MD Vanderbilt Autonomic Dysfunction Center, Vanderbilt University Medical Center
Layout table for additonal information
Responsible Party: ConSynance Therapeutics
ClinicalTrials.gov Identifier: NCT05504395    
Other Study ID Numbers: CSTI-500-003
First Posted: August 17, 2022    Key Record Dates
Last Update Posted: December 7, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ConSynance Therapeutics:
PWS
Phase 1
Single Dose
Non randomized
PK
Safety
Additional relevant MeSH terms:
Layout table for MeSH terms
Prader-Willi Syndrome
Syndrome
Disease
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Obesity
Overnutrition
Nutrition Disorders